$MRVI US Maravai Lifesciences ranked positive on Dec 1st 2020

$MRVI US Maravai Lifesciences ranked positive on Dec 1st 2020

Carl Hull (Co-founder and CEO since 2014) purchased $942,000 of stock on the 25th of November at $26.94. The company recently floated at $27. There was significant subscription by both directors and executives in the IPO with 5 directors spending in total over $3 million and 2 executives spending in total over $700,000. The number and size of these subscriptions and the material investment by the CEO are very encouraging. We are ranking the stock +1.

If you are interested in our Stocks of the Week
those services may also be useful for you


Timely data delivery customised to every user, backed by analysis tools on our internal website


We rank the stocks where transactions are most likely to indicate future share price performance


Studying buyback activity can give a clue to the fortunes of a company and help predict future share price movement

If you are a member of the media and would like to speak with a Smart Insider expert, please contact us press@smartinsider.com or call +44 203 405 3356

Scroll to Top